Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ESC 2026
Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis compared with a natural history cohort
To evaluate the proportion of participants with improved cardiac structure and function at Months 30 and 42 of acoramidis treatment in the ATTRibute-CM cardiac magnetic resonance imaging (CMR) substudy.
In the ATTRibute-CM CMR substudy, long-term acoramidis treatment showed improvement in cardiac function and structure in a sizeable proportion of study participants—about a third for LV systolic function and almost a half for LVMi, respectively, in a conservative analysis.
These findings suggest an alteration of the expected disease trajectory with acoramidis. A larger study is planned to confirm this effect.
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
